BACKGROUND: Human adenovirus-36 (Ad-36) increases adiposity and paradoxically lowers serum cholesterol and triglycerides in chickens, mice, and non-human primates. The role of Ad-36 in human obesity is unknown. OBJECTIVES: To determine the prevalence of Ad-36 antibodies in obese and nonobese humans. To evaluate the association of Ad-36 antibodies with body mass index (BMI) and serum lipids. DESIGN: Cohort study. Volunteers from obesity treatment programs, communities, and a research study. SUBJECTS: Obese and nonobese volunteers at the University of Wisconsin, Madison, WI, and the Bowen Center, Naples, Florida. Obese and thin volunteer research subjects and 89 twin pairs at Columbia University, New York. INTERVENTIONS: Study 1: 502 subjects; serum neutralization assay for antibodies to Ad-2, Ad-31, Ad-36, and Ad-37; serum cholesterol and triglycerides assays. Study 2: BMI and %body fat in 28 twin pairs discordant for Ad-36 antibodies. MAIN OUTCOME MEASURES: Presence of antibodies to adenoviruses, BMI, serum cholesterol and triglycerides levels. RESULTS: Significant (Po0.001) association of obesity and positive Ad-36 antibody status, independent of age, sex, and collection site. Ad-36 antibodies in 30% of obese, 11% of nonobese. Lower serum cholesterol and triglycerides (Po0.003) in Ad-36 antibody-positive vs -negative subjects. Twin pairs: antibody-positive twins had higher BMIs (24.575.2 vs 23.174.5 kg/m 2 , Po0.03) and %body fat (29.679.5% vs 27.579.9%, Po0.04). No association of Ad-2, Ad-31, or Ad-37 antibodies with BMI or serum lipids. CONCLUSIONS: Ad-36 is associated with increased body weight and lower serum lipids in humans. Prospective studies are indicated to determine if Ad-36 plays a role in the etiology of human obesity.
Introduction
Four animal viruses and the scrapie agent are reported to increase adiposity when injected into animals. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] Canine distemper virus produces obesity in mice, probably due to viral-induced hypothalamic damage. [1] [2] [3] [4] [5] Rous-associated virus type 7 (RAV-7) induces a syndrome of obesity, stunted growth, hyperlipidemia, fatty liver, hepatomegaly, anemia, and immune suppression in chickens. 6, 7 Borna virus produces an obesity syndrome in rats characterized by lymphomonocytic inflammation of the hypothalamus, pancreatic islet hyperplasia, and elevated serum glucose and triglycerides levels. 8 Dhurandhar et al 10, 11 reported that an avian adenovirus, SMAM-1, produced excessive deposition of visceral fat and paradoxical reductions of serum cholesterol and triglycerides in chickens. Of 52 obese humans tested, 10 had antibodies to SMAM-1. These individuals had a higher body mass index (BMI) and lower serum cholesterol and triglycerides than did antibody-negative subjects. 12 Our laboratory reported that inoculation of a human adenovirus-36, (Ad-36), into chickens, mice, and non-human primates produces a distinctive syndrome of increased adipose tissue with paradoxically lower serum cholesterol and triglycerides compared to uninfected controls. [13] [14] [15] The current study evaluated the association of positive antibody status to four human adenoviruses, Ad-36, Ad-2, Ad-31, and Ad-37, with body weight and serum lipids in obese and nonobese humans and in twin pairs discordant for Ad-36 antibodies.
Methods
We performed two studies. In Study 1, serum from obese and nonobese volunteers in three American cities was assayed for viral antibodies, cholesterol, and triglycerides. In Study 2, we assayed samples from twin pairs. Written informed consent was obtained for collection of blood samples. The University of Wisconsin Human Subjects Committee approved the protocols.
Subjects, Study 1FObese and nonobese volunteers Blood samples were obtained from 502 subjects from Madison, Wisconsin (WI); Naples, Florida (FL); and New York, (NY) ( Table 1) . Overweight was defined as a BMI of Z25 kg/m 2 , and obesity was defined as a BMI of Z30 kg/ m 2 . 16 Overweight and obese volunteers in Madison and Naples were attending weight reduction programs. Blood was obtained at or near the time of entry into the program in most subjects. Nonobese subjects were volunteers from the University and local communities obtained by word-ofmouth publicity during the period from 1995 to 1999. Aliquots of stored samples were obtained from obese and thin research subjects at the New York Obesity Research Center, who were massively obese (lifetime BMI Z50 kg/m 2 ) or unusually thin (BMI r22 kg/m 2 ) during a period from 1993 to 1998. Race was not specifically ascertained, but of the Madison and Naples subjects, more than 95% were of Caucasian ancestry. In New York, about one-third were black subjects and about one-half were Caucasian. Subjects, Study 2Ftwin samples Serum samples from 89 twin pairs, collected from about 1993 to 1998 for other studies, were screened for antibodies to Ad-36. A total of 26 twin pairs who were discordant for Ad-36 antibody status (20 monozygotic; six dizygotic) had assessments of BMI, cholesterol, and triglyceride levels. Each subject had percent body fat (% body fat) measured using dual-energy X-ray absorptiometry, hydrodensitometry, and/ or bioimpedance analysis. The same body composition method(s) was used within twin pairs.
Development of assays for human adenoviruses
Human adenoviruses types 2 (Ad-2), 31 (Ad-31), 36 (Ad-36), and 37 (Ad-37) from the American Type Culture Collection (ATCC, Manassas, VA, USA) were grown on A549 cells, a human bronchial carcinoma tissue culture line. TCID-50, the dose of virus that produced cell damage (CPE) in 50% of wells, was determined for each virus by standard methods. 13 A sample of Ad-36 virus from a single plaque on a tissue culture plate was plated onto fresh cells and the process repeated three times to obtain a homogenous virus work stock. 13 Use of this purified Ad-36 virus stock (Ad-36P)
increased sensitivity of antibody detection in Ad-36-positive serum samples compared to the original Ad-36 source, so Ad-36P was used in serum neutralization (SN) assays for all but the first 105 samples from Wisconsin, and for all assays from the other sites. SN assays for viral antibodies in serum were performed using the 'constant virus-decreasing serum' method. 13 A virus back-titration was carried out with each assay as a quality check. In all, 100 TCID-50 of the virus was added to the first well of the 96-well plate and serial two-fold dilutions were made. A549 cells were added to the wells and development of CPE was observed. The amount of virus decreases with each dilution, and infectivity was never observed with seven or more dilutions.
Assays for serum cholesterol and triglycerides Serum samples from Wisconsin subjects were assayed for cholesterol and triglycerides by the University of Wisconsin Hospital Clinical Laboratory. Florida and New York serum samples were assayed using cholesterol oxidase-peroxidase colorimetric Sigma kit assays (Sigma, St. Louis, cat #352) with a cholesterol calibrator (Sigma, cat #C 7921) and cardiolipid control (Sigma, cat #C 4571). Subjects from Florida and New York were not necessarily fasting, so triglyceride assays were not performed on their serum.
Statistical analyses Study 1: Ad-36 antibodies in three sites
To test the overall effect of the presence of Ad-36 antibodies on the presence of obesity, we regressed BMI ) as the reference value. Data from all three sites were pooled in a single analysis and potential differences in effects among sites were tested via using interaction terms between two dummy codes for site and Ad-36 status. Data were also analyzed in a secondary analysis separately by site.
To test the effect of Ad-36 on susceptibility to lower serum cholesterol levels, we regressed cholesterol level on Ad-36 antibody status while controlling for age, sex, site of recruitment, and BMI (to control for the greater obesity among the Ad-36-positive subjects) using ordinary leastsquares linear regression. To improve the fit of the data to the parametric assumptions of the analysis, cholesterol was transformed via a Box-Cox transformation 17 by raising cholesterol levels to the power of 0.25. The results were virtually identical when the untransformed data were analyzed. As above, data from all three sites were pooled in a single analysis and potential differences in effects among sites were tested via using interaction terms and then analyzed in a secondary analysis separately by site. Fasting serum for triglycerides assays were available only from Wisconsin, so site-specific analyses were not performed. Data analyses, using a Box-Cox transformation and raising triglycerides levels to the power of 0.25, were similar to those for cholesterol. The results were virtually identical when the untransformed data were analyzed.
Study 2: twins discordant for Ad-36 antibodies A weighted least-squares analysis was applied to the monozygotic and dizygotic twin pairs, followed by t-tests to test for intrapair differences in BMI, serum cholesterol, and triglycerides.
Results
Study 1, Comparison of obese and nonobese subjects Table 1 shows that women outnumbered men in all three sites and that nonobese subjects were younger than obese subjects (Po0.001) in two sites. However, the mean age was similar for Ad-36 antibody-positive (AB þ ) and antibodynegative (ABÀ) subjects (age ¼ 41.7 vs 40.7 y, P ¼ 0.38) ( Table 2 ), suggesting that age did not play a role in susceptibility to infection with Ad-36.
Results of testing for Ad-36 antibodies
Percent antibody positive: When obese subjects from all sites were combined, 30% were Ad-36 AB þ compared to 11% of all the nonobese subjects. The percent of Ad-36 AB þ obese individuals was 27% in Florida, 58% in New York, and 20% in Wisconsin, and the percentages for Ad-36 AB þ nonobese individuals were 14, 9, and 11%, respectively.
Body mass index: In the overall analysis, independent of age and sex, the effect of Ad-36 status on the risk of obesity was highly significant (w 2 (Table 2) . Serum cholesterol and triglycerides: As we previously observed in three species of animals infected with Ad-36, both obese and nonobese subjects who were Ad-36 AB þ had paradoxically lower levels of cholesterol and triglycerides, which were highly significantly different from individuals who were Ad-36 ABÀ (Table 3) . With all subjects combined, serum cholesterols were 5.5170.07 in ABÀ vs 4.6470.11 mmol/l in AB þ (Po0.0001). When data were analyzed separately by site, the estimated effect remained significant (Table 3) . Fasting serum triglycerides were (Table 3) . Examining the data in a different manner by focusing on serum cholesterols, the subjects were divided into quartiles based on serum cholesterol. The lowest quartile of cholesterol had 42% of subjects AB þ for Ad-36 whereas the top quartile had 11% of subjects AB þ . As expected, age increased from the bottom to the top quartile (38.1711.5 vs 43.4711.4, Po0.0007), but BMI was higher in the bottom quartile (41.6715.6 vs 36.7713.1, Po0.008).
Other variables: A total of 31 other variables were evaluated for the first 106 samples from obese subjects in Wisconsin, including waist and hip circumferences, smoking status, blood pressure, pulse rate, high-density lipoproteins (HDL), glucose, uric acid, thyroid function tests (T4, TSH), and other standard lab tests. The age of onset of obesity trended towards significance in subjects positive vs negative for Ad-36 antibodies (17.972.6 vs 13.071.2 y (7s.e.m.), Po0.10). None of the other variables was significantly correlated with antibody status.
Results of testing for Ad-2, Ad-31, and Ad-37
Body weight: In subjects with sufficient sera remaining for the assay, SN assays were performed for antibodies to Ad-2, Ad-31, and Ad-37. The prevalence of antibodies in obese vs nonobese was not different for Ad-2 (76 vs 81%, P ¼ 0.4) or for Ad-31 (70 vs 80%, P ¼ 0.2) ( Table 4) . One obese and four nonobese subjects out of a total of 198 subjects screened had antibodies to Ad-37. These five subjects were not analyzed further. Combining obese and nonobese subjects, analyses revealed no significant differences for age, BMI, or triglycerides between the AB þ and ABÀ subjects for either Ad-2 or Ad-31.
Serum cholesterol and triglycerides: No significant associations of serum cholesterol or triglycerides were noted with Ad-2 or Ad-31 antibody status, with the exception of a significantly lower (Po0.05) serum cholesterol in nonobese subjects positive for Ad-2 antibodies (Table 4) . These results suggest that the increased prevalence of adenovirus antibodies in obese subjects and the paradoxical lowering of serum cholesterol and triglycerides associated with the presence of Ad-36 antibodies is not common to all human adenoviruses.
Study 2, twin studies Studies of Ad-36: Of the 178 twins 40 (22%) had antibodies to Ad-36. Six pairs were concordant Ad-36 AB þ , 56 pairs were concordant ABÀ, and 28 pairs were discordant for Ad-36 antibodies. In the 28 twin pairs who were discordant for Ad-36 antibodies, the individuals who were positive for Ad-36 antibodies were heavier and fatter than their co-twins who did not have Ad-36 antibodies. There were no differences in serum lipids in the discordant twin pairs ( Table 5 ). The specific analyses were as follows:
For both BMI and % body fat, there was a clear effect of Ad-36 status. AB þ twins had a BMI of 26.1 vs 24.5 kg/m 2 (Po0.04) and % body fat was 29.6 vs 27.5 (Po0.04). There were no differences between AB þ and ABÀ for cholesterol and triglycerides.
Studies of Ad-2, Ad-31, and Ad-37: In contrast to Ad-36, there was no association of BMI and antibodies to Ad-2, Ad-31, and Ad-37 in twins discordant for antibodies to these viruses. The BMIs of AB þ vs ABÀ co-twins were 24 37. There were no significant differences in serum cholesterol or triglycerides based on antibody status for any of the three viruses.
Discussion
Animal data show that inoculation of Ad-36 reproducibly produces a syndrome of increased visceral adipose tissue and reduced serum cholesterol and triglycerides in chickens, mice, and non-human primates. [13] [14] [15] Infection of human subjects cannot be performed for ethical reasons, so direct proof that Ad-36 increases body fat and lowers serum lipids in humans will be difficult to obtain. This study demon- Human adenovirus and obesity RL Atkinson et al strated that both obese and nonobese subjects positive for Ad-36 antibodies had significantly higher BMIs and lower serum cholesterol and triglycerides levels compared to ABÀ subjects, thus demonstrating a syndrome similar to animals infected with Ad-36 in the laboratory. These data show an association, but causality for human obesity has not been proven. Our data show that the prevalence of Ad-36 antibodies is almost three-fold higher in obese vs nonobese individuals. To explain this, we considered the possibility that obese people might be more susceptible to Ad-36 infection than nonobese. Our data on antibody status for Ad-2 and Ad-31 offer the most compelling evidence that obese people are not more susceptible to infection. We found that the prevalence of antibodies to Ad-2 and Ad-31 was similar between obese and nonobese, and that these human adenoviruses were not associated with changes in adiposity or serum lipids. Other evidence to refute this hypothesis comes from the literature on antibody formation in obese people. Exposure to Ad-36 would be expected to produce antibodies in both nonobese and obese people. However, there are data suggesting that obese people have impaired immune function. Obese people vaccinated with hepatitis B virus have a reduced prevalence of antibodies, suggesting that immune response to this viral antigen is decreased. 18 This finding might suggest that obese people would be less likely to produce antibodies when exposed to Ad-36 than would lean people. It is unlikely that obese people would be exposed to Ad-36 more often than lean people. Thus, the prevalence of Ad-36 antibodies would be expected to be similar or lower in obese people, not higher. The average age of obese subjects was greater than that of nonobese, but the average age of AB þ subjects was similar among obese and nonobese. Thus, it seems unlikely that an increased chance of viral infection simply due to age could explain the differences in Ad-36 antibody status between obese and nonobese.
Evidence for an association of Ad-36 with increased body weight and adiposity in humans is provided by the twin data in this study. Within pairs, twins normally have a close correlation of body weight and body fat. Bouchard and coworkers [19] [20] [21] [22] demonstrated a higher correlation of body fat and visceral fat within twin pairs, compared to among twin pairs, with or without dietary perturbations. It is possible that there may be other confounding variables not considered, but our findings of a significantly higher BMI and % body fat in the twins with Ad-36 antibodies support the hypothesis that Ad-36 increases adiposity in humans. We cannot explain the lack of a difference in serum lipids in discordant twins pairs, but most pairs were not obese and the length of time from exposure to the virus to our measurements could not be calculated.
Ad-36 appears to differ from other human adenoviruses. There is no immunological crossreactivity between Ad-36 and 47 of the 49 other human adenoviruses in the ATCC. 23, 24 The other human adenoviruses tested in this study, Ad-2, Ad-31, and Ad-37, did not have differences in antibody status between obese and nonobese. Twins discordant for antibodies to these other viruses had no differences in body weight or body fat. Serum cholesterol was lower in nonobese humans positive for Ad-2 antibodies, but levels of serum lipids were not otherwise correlated with presence of antibodies to Ad-2, Ad-31, or Ad-37. It appears that increases in adiposity and reduction of serum lipids are not routine consequences of infection with human adenoviruses.
The mechanisms by which Ad-36 increases adiposity in animals are not yet known. At least two other animal viruses produce obesity in animal models by damaging the hypothalamus. Our preliminary studies in animals did not demonstrate any lesions of the hypothalamus or other areas of the brain. 13 In preliminary studies, we have demonstrated that DNA of Ad-36 may be isolated from adipose tissue of chickens 13 weeks after inoculation, non-human primates after 28 weeks, and in human adipose tissue from autopsies. 25, 26 Also, in vitro studies in the 3T3-L1 tissue culture adipoblast cell line suggest that Ad-36 may alter adipocyte differentiation. 25 As compared to control cells, cells infected with Ad-36 differentiate much faster and accumulate triglycerides more rapidly. A control virus, Ad-2, did not have this effect. We postulate that Ad-36 affects fat cells directly, leading to an increased fat cell number and increased fat cell size. 25 The mechanisms of alterations in serum lipids in both obese and nonobese humans also are unknown. Acute viral infections may lower serum cholesterol, but often produce elevations in serum triglycerides. The other animal models of virus-induced obesity are associated with elevated triglycerides. [1] [2] [3] [4] [5] [6] [7] [8] Finally, it is not clear if the associations of elevated BMI and lowered serum lipids with positive Ad-36 antibody status are linked, or are associated by different mechanisms. None of the other adenoviruses tested had any associations with either BMI or serum lipids, with the exception of Ad-2. Serum cholesterol was higher in the nonobese subjects AB þ for Ad-2, but there were only 10 people in this group and the standard deviation was high, so this may be a chance observation. Ad-36 was first isolated in 1978 in a diabetic child in Germany. 23 More research is needed to determine if Ad-36 Human adenovirus and obesity RL Atkinson et al has played any role in the global epidemic of obesity that has occurred over the last approximately 20 y. 16, 27 
